Key targets of hormonal treatment of prostate cancer. Part 2: The androgen receptor and 5α-reductase

BJU International

Volumn 104, Issue 9, 2009, Pages 1191-1197

  Vis, André N ^a   Schröder, Fritz H ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

5 reductase; Androgen receptor; Cancer; Dustasteride; Finasteride; Prostate

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; DUTASTERIDE; FINASTERIDE; ISOENZYME; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE 1; STEROID 5ALPHA REDUCTASE 2; STEROID 5ALPHA REDUCTASE INHIBITOR;

ANDROGEN DEPRIVATION THERAPY; ANTIANDROGEN THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER HORMONE THERAPY; CANCER INVASION; DRUG EFFICACY; DRUG STRUCTURE; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN LOCALIZATION; QUALITY OF LIFE; REVIEW; SEXUAL FUNCTION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS, HORMONAL; AZASTEROIDS; CLINICAL TRIALS AS TOPIC; FINASTERIDE; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 70349973212     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08743.x     Document Type: Review

References (60)

1. Zhou ZX, Lane MV, Kemppainen JA et al. Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Mol Endocrinol 1995 9 : 208 218
2. Wright AS, Douglas RC, Thomas LN et al. Androgen-induced regrowth in the castrated rat ventral prostate. Role 5 alpha-reductase. Endocrinology 1999 140 : 4509 4515
3. Deslypere JP, Young M, Wilson JD et al. Testosterone and 5 alpha-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol Cell Endocrinol 1992 8 : 15 22
4. Litvinov IV, De Marzo AM, Isaacs JT. Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 2003 88 : 2972 2982
5. Bruchovsky N, Wilson JD. Discovery of the role of dihydrotestosterone in androgen action. Steroids 1999 64 : 753 759
6. Andersson S, Bishop RW, Russell DW. Expression cloning and regulation of steroid 5 alpha-reductase, an enzyme essential for male sexual differentiation. J Biol Chem 1989 16 : 249 255
7. Thigpen AE, Silver RI, Guileyardo JM et al. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest 1993 92 : 903 910
8. Jin Y, Penning TM. Steroid 5alpha-reductases and 3alpha-hydroxysteroid dehydrogenases: key enzymes in androgen metabolism. Best Pract Res Clin Endocrinol Metab 2001 15 : 79 94
9. Tian G, Mook RA Moss ML et al. Mechanism of time-dependent inhibition of 5 alpha-reductases by delta 1-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energies. Biochemistry 1995 34 : 13453 13459
10. Habib FK, Ross M, Bayne CW et al. The localisation and expression of 5 alpha-reductase types I and II mRNAs in human hyperplastic prostate and in prostate primary cultures. J Endocrinol 1998 156 : 509 517
11. Andersson S, Russell DW. Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases. Proc Natl Acad Sci USA 1990 87 : 3640 3644
12. Uemura M, Tamura K, Chung S et al. Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci 2008 99 : 81 6
13. Rittmaster RS, Manning AP, Wright AS et al. Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5 alpha-reductase inhibitor finasteride. Endocrinology 1995 136 : 741 748
14. Locke JA, Guns ES, Lubik AA et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008 68 : 6407 6415
15. Shirakawa T, Gotoh A, Acharya B et al. Messenger RNA levels and enzyme activities of 5 alpha-reductase types 1 and 2 in human benign prostatic hyperplasia (BPH) tissue. Prostate 2004 58 : 33 40
16. Iehlé C, Radvanyi F, Gil Diez de Medina S et al. Differences in steroid 5 alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol 1999 68 : 189 195
17. Nakamura Y, Suzuki T, Nakabayashi M et al. In situ androgen producing enzymes in human prostate cancer. Endocr Relat Cancer 2005 12 : 101 107
18. Bonkhoff H, Stein U, Aumüller G et al. Differential expression of 5 alpha-reductase isoenzymes in the human prostate and prostatic carcinomas. Prostate 1996 29 : 261 267
19. Patel S, Einstein M, Geissler W et al. Immunohistochemical analysis of steroid 5 alpha-reductase type 1 in human scalp and prostate. Ann NY Acad Sci 1996 784 : 27 39
20. Titus MA, Schell MJ, Lih FB et al. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005 11 : 4653 4657
21. Thomas LN, Lazier CB, Gupta R et al. Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 2005 63 : 231 239
22. Thomas LN, Douglas RC, Lazier CB et al. Type 1 and type 2 5 alpha-reductase expression in the development and progression of prostate cancer. Eur Urol 2008 53 : 244 252
23. Thomas LN, Douglas RC, Lazier CB et al. Levels of 5-alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer. J Urol 2008 179 : 147 151
24. Luo J, Dunn TA, Ewing CM et al. Decreased gene expression of steroid 5 alpha reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. Prostate 2003 57 : 134 139
25. Montgomery RB, Mostaghel EA, Vessella R et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008 68 : 4447 4454
26. Xu Y, Dalrymple SL, Becker RE et al. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res 2006 12 : 4072 4079
27. Söderström TG, Bjelfman C, Brekkan E et al. Messenger ribonucleic acid levels of steroid 5-alpha reductase 2 in human prostate predict the enzyme activity. J Clin Endocrinol Metab 2001 86 : 855 858
28. Gormley GJ, Stoner E, Rittmaster RS et al. Effects of finasteride (MK-906), a 5 alpha reductase inhibitor, on circulating androgens in male volunteers. J Clin Endocrinol Metab 1990 70 : 1136 1141
29. Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994 43 : 292 294
30. McConnell JD, Bruskewitz R, Walsh P et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy Safety Study Group. N Engl J Med 1998 338 : 557 563
31. Roehrborn CG, Boyle P, Nickel JC et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002 60 : 434 441
32. Clark RV, Hermann DJ, Cuningham GR et al. Marker suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5-alpha-reductase inhibitor. J Clin Endocrinol Metab 2004 89 : 2179 2184
33. Uygur MC, Arik AI, Altug U et al. Effects of the 5 alpha reductase inhibitor finasteride on serum levels of gonadal, adrenal, and hypophyseal hormones and its clinical significance: a prospective clinical study. Steroids 1998 63 : 208 213
34. Span PN, Voller MC, Smals AG et al. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate. J Urol 1999 161 : 332 337
35. McConnell JD, Wilson JD, George FW et al. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992 74 : 505 508
36. Frye SV. Discovery and clinical development of dutasteride, a potent dual inhibitor 5alpha-reductase inhibitor. Curr Top Med Chem 2006 6 : 405 421
37. DeBruyne F, Barkin J, van Erps P et al. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004 46 : 488 494
38. Andriole G, Humphrey P, Ray P et al. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol 2004 172 : 915 919
39. Rittmaster R, Hahn RG, Ray P et al. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer. Urology 2008 72 : 808 812
40. Gleave M, Qian J, Andreou C et al. The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer - results from a 4-month pre-radical prostatectomy study. Prostate 2006 66 : 1674 1685
41. Rittmaster RS. 5-alpha reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction. Best Pract Res Clin Endocrinol Metab 2008 22 : 389 402
42. Gormley GJ, Stoner E, Bruskewitz RC et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992 327 : 1185 1191
43. Lamb JC, Levy MA, Johnson RK et al. Response of rat and human prostatic cancers to the novel 5 alpha-reductase inhibitor, SK & F 105657. Prostate 1992 21 : 15 34
44. Thompson IA, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003 349 : 215 224
45. Fleshner N, Gomella LG, Cookson Ms et al. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction of Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials 2007 28 : 763 769
46. Eisenberger MA, Laufer M, Volgelzang NJ et al. Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as a possible mechanism of action. Urology 2004 63 : 114 119
47. Presti JC, Fair WR, Andriole G et al. Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. J Urol 1992 148 : 1201 1204
48. Andriole G, Lieber M, Smith J et al. Treatment with finasteride following radical prostatectomy for prostate cancer. Urology 1995 45 : 491 497
49. Fleshner NE, Trachtenberg J. Combination finasteride and flutamide in advanced prostate carcinoma of the prostate: effective therapy with minimal side effects. J Urol 1995 154 : 1642 1646
50. Brufsky A, Fontaine-Rothe P, Berlane K et al. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology 1997 49 : 913 920
51. Ornstein DK, Rao GS, Johnson B et al. Combined finasteride and flutamide therapy in men with advanced prostate cancer. Urology 1996 48 : 901 905
52. Tay MH, Kaufman DS, Regan MM et al. Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate. Ann Oncol 2004 15 : 974 8
53. Barqawi AB, Moul JW, Ziada A et al. Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy. Urology 2003 62 : 872 876
54. Oh WK, Manola J, Bittmann L et al. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. Urology 2003 62 : 99 105
55. Kirby R, Robertson C, Turkes A et al. Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group. Prostate 1999 40 : 105 114
56. Leibowitz RL, Tucker SJ. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients. Oncologist 2001 6 : 177 182
57. Pound CR, Partin AW, Eisenberger MA et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999 281 : 1591 1597
58. Perrotti M, Baroni TE, Abraham C et al. Efficacy of dutasteride in men with PSA relapse following primary local therapy for adenocarcinoma of the prostate. J Urol 2008 179 (Suppl. 180. Abstract 514
59. Shah SK, Trump DL, Sartor O et al. Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. J Urol 2009 181 : 621 626
60. Singh P, Uzgare A, Litvinov I et al. Combinatorial androgen receptor targeted therapy for prostate cancer. Endocr Relat Cancer 2006 13 : 653 66